Market News

6 min read | Updated on July 14, 2026, 08:03 IST
SUMMARY
Grasim will be in focus as Aditya Birla Renewables Ltd (ABRen), a unit of Grasim Industries, has agreed to acquire Sprng Energy from Shell Overseas Investment BV in a deal valued at about $1.8 billion, creating one of India's largest integrated renewable energy platforms.
Stock list

The GIFT NIFTY futures suggest that the NIFTY50 index will open 192 points lower.
The domestic stock market is expected to open gap-down on Tuesday, July 14. The GIFT NIFTY futures suggest that the NIFTY50 index will open 192 points lower.
The transaction values Sprng Energy at an enterprise value of ₹17,200 crore ($1.8 billion), the Aditya Birla Group firm said in a statement.
The price for a barrel of Brent crude oil, the international standard, rose 7.8% to $81.92 after the United States and Iran each said the Strait of Hormuz is under their control. Fighting in the region has kept oil tankers from using the strait to deliver crude from the Persian Gulf to customers worldwide, driving up fuel prices worldwide.
Brent's price jumped toward $80 immediately after President Donald Trump said he's reinstating a blockade on Iranian ships in the strait.
Trump also called for 20% payments on all cargo shipped through it to reimburse the United States for providing protection in the area. Brent's price, though, remains well below its wartime peak of nearly $120 per barrel for its most actively traded contract.
The company said its record $2.4 billion in Q1 bookings, the highest-ever for a first quarter, and a robust deal pipeline reflect resilient demand despite some softness in West Asia.
"We expect strong bookings even in Q2. So, we feel quite positive about the overall outlook," HCLTech CEO and Managing Director C Vijayakumar said.
The HCL Tech board has also approved an investment of up to ₹3,500 crore for setting up data centres in India.
The Noida-headquartered IT services company announced its entry into the full-stack AI market to address the complete spectrum of business opportunities arising from growing demand for AI-led services and solutions across the private sector and government.
According to a regulatory filing, the asset management company posted a 23.1% year-on-year (YoY) surge in its net profit to ₹964.63 crore during the quarter under review, compared with ₹783.64 crore in the June quarter of the 2025-26 financial year (Q1 FY26).
On a sequential basis, its profit advanced by 25.5% YoY from ₹768.58 crore in the quarter-ago period.
The firm’s revenue from operations rose 17.55% YoY to ₹1,564.22 crore in the June quarter of FY27, as against ₹1,330.67 crore in the corresponding period of the previous fiscal year.
Ireland-based lessors Sky High LXXX Leasing Company Ltd and Sky High LXXVII Leasing Company Ltd have filed IDERA Deregistration requests for the four planes with the Directorate General of Civil Aviation (DGCA), according to public notices.
IDERA refers to Irrevocable Deregistration and Export Request Authorisation, a framework that allows lessors to directly approach a country's aviation regulator to take back leased aircraft.
The four aircraft whose deregistration has been sought are VT-MXA, VT-MXC, VT-MAX and VT-MXB.
The company earlier had a net profit of ₹133.16 crore in the April-June quarter a year ago, according to a regulatory filing from Nuvoco Vistas Corp.
Its revenue from operations was up 8.9% to ₹3,128.71 crore in the June quarter. It was at ₹2,872.70 crore in the corresponding quarter a year ago.
Total expenses of Nuvoco Vistas were at ₹2,856.30 crore, up 6.34% in the June quarter of FY27.
Its total income, which includes other income, was at ₹3,132.32 crore, up 8.47% in Q1 FY27.
Mylan is expected to offload around 9.2 crore shares at a floor price of ₹378.5 per share, representing an 8% discount to Biocon's previous closing price. The transaction is estimated to be worth nearly ₹3,500 crore.
The US Food and Drug Administration (USFDA) had conducted an inspection from March 3, 2025, to March 7, 2025, at the company's bioequivalence facility at Vadodara in Gujarat, Alembic Pharmaceuticals said in a regulatory filing.
The company has been made aware that the US Food and Drug Administration (USFDA) has issued a warning letter dated July 10, 2026, to the Clinical Investigator associated with a bioequivalence study conducted at the company's bioequivalence facility, it added.
Related News
About The Author

Next Story
How To Use Open Interest For Intraday Trading: Complete Guide
What Is Stop Loss In Trading? Meaning, Types, & How To Use It
What Is ICRA? Why Its Credit Ratings Matter To Investors
Explore Learning Centre
All topics · stocks, MFs, derivatives, IPOs